Compare Gilead Sciences, Inc. (GILD) vs International Paper Company Common Stock (IP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs International Paper Company Common Stock — how do they compare? Gilead Sciences, Inc. trades at $159.21 (market cap $190.38B), while International Paper Company Common Stock trades at $33.11 (market cap $16.89B). The key difference: Gilead Sciences, Inc. is far larger — about 11.3× International Paper Company Common Stock's market cap, and International Paper Company Common Stock pays the higher dividend (5.8%). Which is the better fit depends on your goals — on Pluang, investors hold Gilead Sciences, Inc. for 112 Days and International Paper Company Common Stock for 0 Days on average.
| GILD | IP | |
|---|---|---|
Market Cap | $190.38B | $16.89B |
Volume | 5,758,183 | 3,140,672 |
Sector | Health | Basic Materials |
52-Week High | $155.80 | $49.19 |
52-Week Low | $117.85 | $29.38 |
Typical Hold Time | 112 Days | 0 Days |
Enterprise Value | $213.45B | $25.86B |
Dividend Yield | 2.14% | 5.8% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $147.92, down 1.67% on the day, with a bullish technical outlook supported by moving averages and a consensus analyst price target of $153.13. Recent earnings beat expectations in three consecutive quarters, though Q3 2026 results are pending. The company maintains strong operating cash flow of $10.02B in 2025 and has expanded HIV prevention access through a new PAHO partnership in Latin America.
Investment outlook remains positive with 67% analyst buy ratings and potential upside to price targets, though risks include negative net income margin (-10.64%) projected for 2026 and elevated debt levels. The stock's valuation appears reasonable with a P/E of 17.84, but investors should monitor earnings sustainability and pipeline developments in oncology and HIV therapies.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About International Paper Company Common Stock
International Paper Company is a US producer of fiber-based packaging, pulp, and paper products, manufacturing corrugated packaging and containerboard used to ship and protect goods.
Read more on IP →
